SuperworthElicio Therapeutics EPS ELTX
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$2.18
- Latest quarter, Q2 FY26
- −$0.43
- Fiscal year 2025
- −$2.63
Elicio Therapeutics' earnings per share was −$2.18 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.43.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.63 | n/a |
| FY2024 | −$4.21 | n/a |
| FY2023 | −$29.70 | n/a |
| FY2022 | −$52.77 | n/a |
| FY2021 | −$21.70 | n/a |
| FY2020 | −$54.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.43 | n/a | −$2.18 | |
| Q1 FY26 | −$0.65 | n/a | −$2.41 | |
| Q4 FY25 | −$0.50 | n/a | −$2.63 | |
| Q3 FY25 | −$0.60 | n/a | −$3.16 | |
| Q2 FY25 | −$0.66 | n/a | −$3.95 | |
| Q1 FY25 | −$0.87 | n/a | −$3.93 | |
| Q4 FY24 | −$1.03 | n/a | −$4.21 | |
| Q3 FY24 | −$1.39 | n/a | −$4.23 | |
| Q2 FY24 | −$0.64 | n/a | −$4.11 | |
| Q1 FY24 | −$1.15 | n/a | −$6.08 | |
| Q4 FY23 | −$1.05 | n/a | −$29.70 | |
| Q3 FY23 | −$1.27 | n/a | −$30.75 |
Against its peers
Companies in Drug Manufacturers - General nearest Elicio Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ELTXElicio Therapeutics | −$2.18 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Elicio Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.